PTK2 and breast carcinoma: In a previous study, FAK-copy-gain was observed in 18% of breast cancer tissues [15], with higher FAK expression in the triple negative subgroup [14]; similarly, our analyses of TCGA and METABRIC breast cancer cases showed that over 15% of breast cancer cases had FAK-copy-gain, as is consistent with our finding of frequent FAK-copy-gains in NCI-60 cells, thereby suggesting that many breast cancer cases can be candidates for FAK-inhibitor chemotherapy.